Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477607 · ClinicalTrials.gov registry record · Phase 2
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
A Phase 2 study of Ototoxicity and Unspecified Adult Solid Tumor, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT00477607 is a Phase 2 study of Ototoxicity and Unspecified Adult Solid Tumor that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 39 participants, below the 148-participant average among 3 other Ototoxicity trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00477607, a Phase 2 study of Ototoxicity and Unspecified Adult Solid Tumor, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG alpha-lipoic acid
- BEHAVIORAL Audiology
- BIOLOGICAL laboratory biomarker analysis
Study Locations (2)
Oregon
- VA Medical Center, Portland - Portland
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477607
The ClinicalTrials.gov registry entry for NCT00477607 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148-participant average among 3 other Ototoxicity trials with a reported enrollment target (74% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ototoxicity appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00477607 reports 2 study locations spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00477607 about?
NCT00477607 is a clinical study titled "Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin". RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin.
What is the current status of trial NCT00477607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2007-10. Estimated completion is 2011-06.
What conditions does trial NCT00477607 study?
This clinical trial studies the following conditions: Ototoxicity, Unspecified Adult Solid Tumor.
What interventions are being tested in trial NCT00477607?
The interventions under investigation include: Placebo (DRUG), alpha-lipoic acid (DRUG), Audiology (BEHAVIORAL), laboratory biomarker analysis (BIOLOGICAL).
Who is sponsoring clinical trial NCT00477607?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00477607 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ototoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
RECRUITING · Phase 2
-
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
COMPLETED · Phase 1
-
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.